Incyte Corporation (INCY) Highlights Sustained Efficacy of Opzelura Through Week 24
On May 7, INCY reported final 24-week results from its Phase 3 TRuE-AD4 study evaluating Opzelura (ruxolitinib) cream in adults with moderate atopic dermatitis who had limited response or intolerance ...







